Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis

Robert Jackson, Marilyn K Glassberg Csete, Carol F. Ramos, Pablo A. Bejarano, Ghazwan Butrous, Orlando Orlando Gómez-Marín

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia characterized by temporally and spatially heterogeneous fibroblast proliferation and poor prognosis. No therapies have been shown in randomized clinical trials (RCT) to influence survival. Twenty-nine subjects were assigned randomly in a pilot study to a double-blind, placebo-controlled, RCT to test sildenafil in patients with IPF with forced vital capacity 40-90% and diffusing capacity 30-90% of predicted. During the 6-month experimental treatment period, patients underwent 6-min walk tests and estimation of dyspnea using the Borg scale at baseline (0 months), 3 months, and 6 months. Participants had moderate impairment of pulmonary function, and there were no significant differences between placebo (n = 15) and sildenafil (n = 14)-treated groups. Sildenafil did not significantly increase 6-min walk test distance (mean distance ± SD after 6-month protocol: placebo 355 ± 82 m, sildenafil 324 ± 41 m; p = 0.256) nor did it lessen dyspnea after exercise (mean Borg score after 6-month protocol: placebo 3.4 ± 1.6, sildenafil 4.1 ± 2.3; p = 0.492). Adverse reactions were few and minor in nature. In this trial, sildenafil did not significantly increase 6-min walk test distance or decrease the Borg dyspnea index in patients with clinically typical IPF. This trial was registered at clinicaltrials.gov as NCT00359736.

Original languageEnglish
Pages (from-to)115-123
Number of pages9
JournalLung
Volume188
Issue number2
DOIs
StatePublished - Apr 1 2010

Fingerprint

Idiopathic Pulmonary Fibrosis
Exercise Tolerance
Placebos
Dyspnea
Therapeutics
Randomized Controlled Trials
Idiopathic Interstitial Pneumonias
Vital Capacity
Sildenafil Citrate
Fibroblasts
Exercise
Lung
Survival
Walk Test

Keywords

  • Exercise
  • Idiopathic pulmonary fibrosis
  • Pulmonary hypertension
  • Sildenafil
  • Vasodilator

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Jackson, R., Glassberg Csete, M. K., Ramos, C. F., Bejarano, P. A., Butrous, G., & Orlando Gómez-Marín, O. (2010). Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung, 188(2), 115-123. https://doi.org/10.1007/s00408-009-9209-8

Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. / Jackson, Robert; Glassberg Csete, Marilyn K; Ramos, Carol F.; Bejarano, Pablo A.; Butrous, Ghazwan; Orlando Gómez-Marín, Orlando.

In: Lung, Vol. 188, No. 2, 01.04.2010, p. 115-123.

Research output: Contribution to journalArticle

Jackson, R, Glassberg Csete, MK, Ramos, CF, Bejarano, PA, Butrous, G & Orlando Gómez-Marín, O 2010, 'Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis', Lung, vol. 188, no. 2, pp. 115-123. https://doi.org/10.1007/s00408-009-9209-8
Jackson, Robert ; Glassberg Csete, Marilyn K ; Ramos, Carol F. ; Bejarano, Pablo A. ; Butrous, Ghazwan ; Orlando Gómez-Marín, Orlando. / Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. In: Lung. 2010 ; Vol. 188, No. 2. pp. 115-123.
@article{5485fd7c544c4e74877258d775957049,
title = "Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis",
abstract = "Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia characterized by temporally and spatially heterogeneous fibroblast proliferation and poor prognosis. No therapies have been shown in randomized clinical trials (RCT) to influence survival. Twenty-nine subjects were assigned randomly in a pilot study to a double-blind, placebo-controlled, RCT to test sildenafil in patients with IPF with forced vital capacity 40-90{\%} and diffusing capacity 30-90{\%} of predicted. During the 6-month experimental treatment period, patients underwent 6-min walk tests and estimation of dyspnea using the Borg scale at baseline (0 months), 3 months, and 6 months. Participants had moderate impairment of pulmonary function, and there were no significant differences between placebo (n = 15) and sildenafil (n = 14)-treated groups. Sildenafil did not significantly increase 6-min walk test distance (mean distance ± SD after 6-month protocol: placebo 355 ± 82 m, sildenafil 324 ± 41 m; p = 0.256) nor did it lessen dyspnea after exercise (mean Borg score after 6-month protocol: placebo 3.4 ± 1.6, sildenafil 4.1 ± 2.3; p = 0.492). Adverse reactions were few and minor in nature. In this trial, sildenafil did not significantly increase 6-min walk test distance or decrease the Borg dyspnea index in patients with clinically typical IPF. This trial was registered at clinicaltrials.gov as NCT00359736.",
keywords = "Exercise, Idiopathic pulmonary fibrosis, Pulmonary hypertension, Sildenafil, Vasodilator",
author = "Robert Jackson and {Glassberg Csete}, {Marilyn K} and Ramos, {Carol F.} and Bejarano, {Pablo A.} and Ghazwan Butrous and {Orlando G{\'o}mez-Mar{\'i}n}, Orlando",
year = "2010",
month = "4",
day = "1",
doi = "10.1007/s00408-009-9209-8",
language = "English",
volume = "188",
pages = "115--123",
journal = "Lung",
issn = "0341-2040",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis

AU - Jackson, Robert

AU - Glassberg Csete, Marilyn K

AU - Ramos, Carol F.

AU - Bejarano, Pablo A.

AU - Butrous, Ghazwan

AU - Orlando Gómez-Marín, Orlando

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia characterized by temporally and spatially heterogeneous fibroblast proliferation and poor prognosis. No therapies have been shown in randomized clinical trials (RCT) to influence survival. Twenty-nine subjects were assigned randomly in a pilot study to a double-blind, placebo-controlled, RCT to test sildenafil in patients with IPF with forced vital capacity 40-90% and diffusing capacity 30-90% of predicted. During the 6-month experimental treatment period, patients underwent 6-min walk tests and estimation of dyspnea using the Borg scale at baseline (0 months), 3 months, and 6 months. Participants had moderate impairment of pulmonary function, and there were no significant differences between placebo (n = 15) and sildenafil (n = 14)-treated groups. Sildenafil did not significantly increase 6-min walk test distance (mean distance ± SD after 6-month protocol: placebo 355 ± 82 m, sildenafil 324 ± 41 m; p = 0.256) nor did it lessen dyspnea after exercise (mean Borg score after 6-month protocol: placebo 3.4 ± 1.6, sildenafil 4.1 ± 2.3; p = 0.492). Adverse reactions were few and minor in nature. In this trial, sildenafil did not significantly increase 6-min walk test distance or decrease the Borg dyspnea index in patients with clinically typical IPF. This trial was registered at clinicaltrials.gov as NCT00359736.

AB - Idiopathic pulmonary fibrosis (IPF) is a form of idiopathic interstitial pneumonia characterized by temporally and spatially heterogeneous fibroblast proliferation and poor prognosis. No therapies have been shown in randomized clinical trials (RCT) to influence survival. Twenty-nine subjects were assigned randomly in a pilot study to a double-blind, placebo-controlled, RCT to test sildenafil in patients with IPF with forced vital capacity 40-90% and diffusing capacity 30-90% of predicted. During the 6-month experimental treatment period, patients underwent 6-min walk tests and estimation of dyspnea using the Borg scale at baseline (0 months), 3 months, and 6 months. Participants had moderate impairment of pulmonary function, and there were no significant differences between placebo (n = 15) and sildenafil (n = 14)-treated groups. Sildenafil did not significantly increase 6-min walk test distance (mean distance ± SD after 6-month protocol: placebo 355 ± 82 m, sildenafil 324 ± 41 m; p = 0.256) nor did it lessen dyspnea after exercise (mean Borg score after 6-month protocol: placebo 3.4 ± 1.6, sildenafil 4.1 ± 2.3; p = 0.492). Adverse reactions were few and minor in nature. In this trial, sildenafil did not significantly increase 6-min walk test distance or decrease the Borg dyspnea index in patients with clinically typical IPF. This trial was registered at clinicaltrials.gov as NCT00359736.

KW - Exercise

KW - Idiopathic pulmonary fibrosis

KW - Pulmonary hypertension

KW - Sildenafil

KW - Vasodilator

UR - http://www.scopus.com/inward/record.url?scp=77949875047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949875047&partnerID=8YFLogxK

U2 - 10.1007/s00408-009-9209-8

DO - 10.1007/s00408-009-9209-8

M3 - Article

VL - 188

SP - 115

EP - 123

JO - Lung

JF - Lung

SN - 0341-2040

IS - 2

ER -